Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Retained Earnings (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Retained Earnings data on record, last reported at -$108.4 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 13.81% year-over-year to -$108.4 million; the TTM value through Sep 2025 reached -$108.4 million, down 13.81%, while the annual FY2024 figure was -$98.0 million, 12.23% down from the prior year.
  • Retained Earnings reached -$108.4 million in Q3 2025 per COEP's latest filing, down from -$106.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$3.6 million in Q1 2022 and bottomed at -$108.4 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$60.1 million, with a median of -$77.3 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: surged 58.23% in 2022, then crashed 1953.64% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$27.6 million in 2021, then crashed by 139.89% to -$66.1 million in 2022, then tumbled by 32.18% to -$87.4 million in 2023, then dropped by 12.23% to -$98.0 million in 2024, then dropped by 10.55% to -$108.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$108.4 million in Q3 2025, -$106.0 million in Q2 2025, and -$101.7 million in Q1 2025.